Abstract
favipiravir in non-human primates (NHP) in order to guide future efficacy studies of favipiravir 23 in large animal models.
24
Four different studies were conducted in 30 uninfected cynomolgus macaques of Chinese 25 (n=17) or Mauritian (n=13) origin treated with intravenous favipiravir for 7 to 14 days with 
143
Pharmacokinetic and residual error models were selected using data of the one-week study 1A.
144
We started with a mono-compartmental model with linear elimination. Because a non-linearity 145 was observed in the non-compartmental analysis (see results), we also tested a model with a
146
Michaelis-Menten elimination, a model with both zero order and first order elimination, a 147 model with both first order and Michaelis-Menten eliminations and a model with both first 148 order and nonlinear eliminations depending of favipiravir plasma concentration levels (see 149 equation 1), accounting for the aldehyde oxidase pathway. All these models were tested 150 assuming exponential random effects on all parameters with a diagonal variance matrix for the 151 random effects.
152
Next data from study 1B were added; as it was a two-week study, time effect was tested on 153 elimination and enzyme parameters. Additions of linear, inverse tangent and exponential time 154 function on elimination and enzyme parameters, as well as feedback effect on enzyme 155 production, were tested. The effect of sex and anesthesia (since the design of the studies does 156 not allow to separate them) was evaluated. Finally data from studies 2A and 2B were added and the parameters were re-estimated to assess the effect of NHP origin (China and Mauritius Island 158 for studies 1 and 2, respectively) and relevant random effects were selected.
159
Model estimation was performed using nonlinear mixed effect model and the software Monolix 
174
Simulation studies with different dosing regimens. We used the final PK model to evaluate 175 by simulation the drug exposure that could be achieved during two weeks of favipiravir with a 176 loading dose of 200 or 250 mg/kg BID the first day followed by a maintenance dose from 60 177 to 180 mg/kg BID. In order to take into account the possible reduction in drug concentration 178 over time (see results), we also evaluated scenarios where the dosing regimen increased in the 179 second week of treatment. For each scenario 5,000 in silico PK profiles with frequent sampling 180 measurements were generated using mlxR package (http://simulx.webpopix.org/mlxr/) and 181 daily Cave, Ctrough and Cmax were provided. and -2 (-0.9;-2.5) g/dL from baseline to D14 in studies 1B and 2A. In study 1B, in macaques us to fit the data and to make predictions for a variety of unobserved scenarios.
295
The complexity of the drug PK and the large variability in drug concentrations across animals study 2B. Diet (pellets, fruit) was given daily, water was available throughout the day.
580
Macaques were assigned to the test groups using body weights before initial dosing by weight-581 stratified randomization. for one animal (4 days), was observed in 3 animals in study 1B and 6 animals in study 2B.
589
Stereotypies, described as intermittent backward head movements, were reported only in 590 studies 2A and 2B, respectively in one and two animals.
591
Food consumption had large intra and inter individual variability along the studies ( Figure A1 ).
592
Transient decrease of food consumption was observed in the four studies within the 3 days after 593 treatment initiation, followed with clear rebound, excepted in the study 1B group receiving 150 Agreement between the two assays was stated by the cross validation study. Method B slightly 674 under-predicts peak concentrations of favipiravir, and over predicts residual concentrations
675
( Figures A3 and A4 ). However, only two absolute relative errors were higher than 15%, one is 676 positive and the second negative, and the relative bias was computed to -1.1%, so is quite low. 
